FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807004674> ?p ?o ?g. }

• W2807004674 endingPage "919" @default.
• W2807004674 startingPage "911" @default.
• W2807004674 abstract "Antiangiogenic therapy has shown promising results in preclinical and clinical trials. However, tumor cells acquire resistance to this therapy by gaining ability to survive and proliferate under hypoxia induced by antiangiogenic therapy. Combining antiangiogenic therapy with hypoxia-activated prodrugs can overcome this limitation. Here, we have tested the combination of antiangiogenic drug sunitinib in combination with hypoxia-activated prodrug evofosfamide in neuroblastoma. In vitro, neuroblastoma cell line SK-N-BE(2) was 40-folds sensitive to evofosfamide under hypoxia compared to normoxia. In IV metastatic model, evofosfamide significantly increased mice survival compared to the vehicle (P=.02). In SK-N-BE(2) subcutaneous xenograft model, we tested two different treatment regimens using 30 mg/kg sunitinib and 50 mg/kg evofosfamide. Here, sunitinib therapy when started along with evofosfamide treatment showed higher efficacy compared to single agents in subcutaneous SK-N-BE(2) xenograft model, whereas sunitinib when started 7 days after evofosfamide treatment did not have any advantage compared to treatment with either single agent. Immunofluorescence of tumor sections revealed higher number of apoptotic cells and hypoxic areas compared to either single agent when both treatments were started together. Treatment with 80 mg/kg sunitinib with 50 mg/kg evofosfamide was significantly superior to single agents in both xenograft and metastatic models. This study confirms the preclinical efficacy of sunitinib and evofosfamide in murine models of aggressive neuroblastoma. Sunitinib enhances the efficacy of evofosfamide by increasing hypoxic areas, and evofosfamide targets hypoxic tumor cells. Consequently, each drug enhances the activity of the other." @default.
• W2807004674 created "2018-06-13" @default.
• W2807004674 creator A5000510528 @default.
• W2807004674 creator A5003642180 @default.
• W2807004674 creator A5005931876 @default.
• W2807004674 creator A5012704417 @default.
• W2807004674 creator A5026699953 @default.
• W2807004674 creator A5034253917 @default.
• W2807004674 creator A5036023565 @default.
• W2807004674 creator A5038794162 @default.
• W2807004674 creator A5042870042 @default.
• W2807004674 creator A5049914982 @default.
• W2807004674 creator A5074827796 @default.
• W2807004674 creator A5089659655 @default.
• W2807004674 date "2018-08-01" @default.
• W2807004674 modified "2023-10-17" @default.
• W2807004674 title "Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models" @default.
• W2807004674 cites W1605399277 @default.
• W2807004674 cites W1606356514 @default.
• W2807004674 cites W1967600348 @default.
• W2807004674 cites W1976605228 @default.
• W2807004674 cites W1994557380 @default.
• W2807004674 cites W2009991551 @default.
• W2807004674 cites W2017322644 @default.
• W2807004674 cites W2024903578 @default.
• W2807004674 cites W2039660061 @default.
• W2807004674 cites W2082594665 @default.
• W2807004674 cites W2082746308 @default.
• W2807004674 cites W2087565365 @default.
• W2807004674 cites W2096539632 @default.
• W2807004674 cites W2104928951 @default.
• W2807004674 cites W2105653042 @default.
• W2807004674 cites W2130002311 @default.
• W2807004674 cites W2140088548 @default.
• W2807004674 cites W2156902079 @default.
• W2807004674 cites W2157943512 @default.
• W2807004674 cites W2158474413 @default.
• W2807004674 cites W2162527266 @default.
• W2807004674 cites W2172015659 @default.
• W2807004674 cites W2206903933 @default.
• W2807004674 cites W2255357451 @default.
• W2807004674 cites W2359012815 @default.
• W2807004674 cites W2492950248 @default.
• W2807004674 cites W2565599911 @default.
• W2807004674 doi "https://doi.org/10.1016/j.tranon.2018.05.004" @default.
• W2807004674 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6041570" @default.
• W2807004674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29803017" @default.
• W2807004674 hasPublicationYear "2018" @default.
• W2807004674 type Work @default.
• W2807004674 sameAs 2807004674 @default.
• W2807004674 citedByCount "10" @default.
• W2807004674 countsByYear W28070046742019 @default.
• W2807004674 countsByYear W28070046742020 @default.
• W2807004674 countsByYear W28070046742021 @default.
• W2807004674 countsByYear W28070046742023 @default.
• W2807004674 crossrefType "journal-article" @default.
• W2807004674 hasAuthorship W2807004674A5000510528 @default.
• W2807004674 hasAuthorship W2807004674A5003642180 @default.
• W2807004674 hasAuthorship W2807004674A5005931876 @default.
• W2807004674 hasAuthorship W2807004674A5012704417 @default.
• W2807004674 hasAuthorship W2807004674A5026699953 @default.
• W2807004674 hasAuthorship W2807004674A5034253917 @default.
• W2807004674 hasAuthorship W2807004674A5036023565 @default.
• W2807004674 hasAuthorship W2807004674A5038794162 @default.
• W2807004674 hasAuthorship W2807004674A5042870042 @default.
• W2807004674 hasAuthorship W2807004674A5049914982 @default.
• W2807004674 hasAuthorship W2807004674A5074827796 @default.
• W2807004674 hasAuthorship W2807004674A5089659655 @default.
• W2807004674 hasBestOaLocation W28070046741 @default.
• W2807004674 hasConcept C121608353 @default.
• W2807004674 hasConcept C126322002 @default.
• W2807004674 hasConcept C178790620 @default.
• W2807004674 hasConcept C185592680 @default.
• W2807004674 hasConcept C2776715637 @default.
• W2807004674 hasConcept C2779490328 @default.
• W2807004674 hasConcept C2780035454 @default.
• W2807004674 hasConcept C502942594 @default.
• W2807004674 hasConcept C540031477 @default.
• W2807004674 hasConcept C54355233 @default.
• W2807004674 hasConcept C71924100 @default.
• W2807004674 hasConcept C7836513 @default.
• W2807004674 hasConcept C81885089 @default.
• W2807004674 hasConcept C86803240 @default.
• W2807004674 hasConcept C98274493 @default.
• W2807004674 hasConceptScore W2807004674C121608353 @default.
• W2807004674 hasConceptScore W2807004674C126322002 @default.
• W2807004674 hasConceptScore W2807004674C178790620 @default.
• W2807004674 hasConceptScore W2807004674C185592680 @default.
• W2807004674 hasConceptScore W2807004674C2776715637 @default.
• W2807004674 hasConceptScore W2807004674C2779490328 @default.
• W2807004674 hasConceptScore W2807004674C2780035454 @default.
• W2807004674 hasConceptScore W2807004674C502942594 @default.
• W2807004674 hasConceptScore W2807004674C540031477 @default.
• W2807004674 hasConceptScore W2807004674C54355233 @default.
• W2807004674 hasConceptScore W2807004674C71924100 @default.
• W2807004674 hasConceptScore W2807004674C7836513 @default.
• W2807004674 hasConceptScore W2807004674C81885089 @default.
• W2807004674 hasConceptScore W2807004674C86803240 @default.

• next